Shopping Cart
Your Cart is Empty
Quantity:
Subtotal
Taxes
Shipping
Total
There was an error with PayPalClick here to try again
CelebrateThank you for your business!You should be receiving an order confirmation from Paypal shortly.Exit Shopping Cart

North Central Neurology Associates, P.C.

Joanne P. LaGanke MS Center


              CLINICAL TRIALS: OPEN FOR ENROLLMENT

Gemini 2- EFC16034: A Phase 3 Trial with no placebo, comparing Tolebrutinib vs. Aubagio(FDA Approved) for safety and efficacy in a comparative trial. Looking for patients between the ages of 19-55 with a diagnoses of MS. If you have had a relapse within the last year and do not have any active or chronic infections requiring treatment and are interested, please contact [email protected] 

Fenhance 2- GN42272: Looking for patients between the ages of 19-55, have been diagnosed with MS in the previous 10 years, have had a relapse within the last year, and have no history of GI problems. If you are interested, please contact Marla Morris at [email protected]

Enlighten: Ozanimod(Zeposia) open label with no placebo trial. Looking for patients who have been diagnosed with MS within the previous 5 years or less. Looking for patients between the ages of 19-65 that have been on one or less approved Disease Modifying Therapy(DMT). If you are interested, please contact Tyler at [email protected] 

Artios- COMB157GUS23101: Looking for patients who are starting Ofatumumab after transitioning off from either Gilenya or Tecfidera which they had been on for at least 6 months as their last DMT. Must be between the ages of 19-60 with no history of Neuromyelitis Optica. Must have treatment history with a maximum of 3 DMT's. If interested please contact Gena Hamilton at [email protected]

CBD Oil-EHP-MS-101: Looking for patients who have a diagnosis of MS between the ages of 19-55 who have had a relapse within the previous year. Must be willing to come off of all cannabis products for the duration of the trial (6 months). If interested, please contact Tyler at [email protected] 

SOSTOS-COMB157GUS09: Open label comparative trial using Ofatumumab 20mg SQ monthly vs. DMT of their choice. Looking for patients between the ages of 19-45 who have a diagnosis of MS. Must be on a DMT for 6 months before enrollment of trial. No Lemtrada, Tysabri, Mavenclad, or Ocrevus. If interested, please contact Gena Hamilton at [email protected]

ANK-700: A Phase 1 Trial consisting of 3 infusions. Placebo controlled. No relapses required prior to trial. Patients can be on either Vumerity or Tecfidera while taking infusions or no DMT. Trial should be starting in July 2022. If interested please contact Marla Morris at [email protected]